Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications

Authors

  • Simone Fulda,

    1. Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Frankfurt, Germany
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Krishnaraj Rajalingam,

    1. Institute of Biochemistry II, Goethe University School of Medicine, Frankfurt am Main, Germany
    Search for more papers by this author
    • These authors contributed equally to this work.

  • Ivan Dikic

    Corresponding author
    1. Institute of Biochemistry II, Goethe University School of Medicine, Frankfurt am Main, Germany
    2. Frankfurt Institute for Molecular Life Sciences and Institute of Biochemistry II, Goethe University School of Medicine, Frankfurt am Main, Germany
    • Tel.: +49 69 6301 83647; Fax: +49 69 6301 5577

    Search for more papers by this author

Abstract

Conjugation of ubiquitin to proteins (ubiquitylation) has emerged to be one of the most crucial post-translational modifications controlling virtually all cellular processes. What was once regarded as a mere signal for protein degradation has turned out to be a major regulator of molecular signalling networks. Deregulation of ubiquitin signalling is closely associated with various human pathologies. Here, we summarize the current knowledge of ubiquitin signalling in immune deficiencies and cancer as well as the available therapeutic strategies targeting the ubiquitin system in combating these pathogenic conditions.

Ancillary